Nuformix plc (LSE:NFX), a pharmaceutical development company focusing on fibrosis and oncology through drug repurposing, announced on Monday that it has submitted a draft application for Orphan Drug Designation (ODD) to the European Medicines Agency (EMA) for its lead asset, NXP002.
This drug is being developed as an inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF), a severe respiratory condition with limited therapeutic options.
The draft submission precedes a pre-submission meeting with the EMA, scheduled for later in January 2025. Following the meeting, the company anticipates submitting the formal ODD application, with updates on the review timeline and decision expected shortly thereafter.
In parallel, Nuformix is actively engaged in discussions with potential partners to secure an out-licence or option agreement for NXP002, underscoring its commercial potential.
Nuformix specialises in developing novel drug forms with improved properties to address unmet medical needs. Its pipeline of preclinical assets offers significant value and early licensing opportunities, leveraging innovative approaches to drug repurposing.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024